STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology

EXCLUSIVE: Harmony Biosciences’ CEO, Jeffrey Dayno, on Innovation and Expanding Patient Impact

byLiliana Vida
October 29, 2024
in Biotechnology, Q&A's, Small-Cap
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

Stoxpo: Harmony Biosciences has shown strong growth with WAKIX. What factors are behind this performance?

Jeffrey Dayno: Our growth is rooted in our commitment to addressing significant unmet needs in neuroscience. WAKIX, as a non-scheduled treatment for excessive daytime sleepiness in adults with narcolepsy, stands out in the market due to its unique mechanism of action. We’ve dedicated significant resources to expanding access, raising awareness, and supporting both patients and healthcare providers, which has strengthened WAKIX’s presence. Additionally, ongoing post-marketing studies and our exploration of WAKIX’s potential in other indications will allow us to help a broader patient community.

Stoxpo: Beyond WAKIX, what’s in Harmony’s pipeline that investors and patients should keep an eye on?

Jeffrey Dayno: We’re especially excited about HBS-102, a drug targeting the melanin-concentrating hormone receptor pathway, which plays a critical role in sleep and other neurological functions. It’s still early in its development, but we see strong promise in HBS-102’s potential to treat additional rare neurological disorders. We’re also continuously looking for partnerships and acquisitions that align with our mission to expand and enhance our portfolio.

Stoxpo: You’ve focused on rare neurological diseases. Do you see further expansion into other areas?

Jeffrey Dayno: While we remain centered on neuroscience and rare, underserved conditions, we’re always open to exploring adjacent opportunities where we can create meaningful impact. With neurological disorders on the rise, particularly those like narcolepsy and central nervous system disorders, we see room for innovation. We plan to stay focused but flexible, building a diverse pipeline that supports patients, caregivers, and the medical community.

Stoxpo: How does Harmony plan to sustain growth and remain competitive?

Jeffrey Dayno: Our strategy is rooted in innovation and patient support. We’re committed to investing in R&D, expanding our commercial reach, and enhancing educational resources for patients and providers. Real-world data helps us refine our approach with WAKIX and sets the foundation for future products. We balance organic growth with strategic M&A to diversify our portfolio and strengthen our position in the market.

Stoxpo: The narcolepsy treatment landscape has seen growth. What sets Harmony apart?

Jeffrey Dayno: Harmony is dedicated to providing safe, effective, and non-scheduled treatment options for narcolepsy. WAKIX’s novel mechanism of action has established it as a trusted treatment in the community. Our focus isn’t only on treating symptoms but also on enhancing quality of life. By consistently seeking feedback from the narcolepsy community, we can address real needs and reinforce WAKIX’s role in narcolepsy care.

Stoxpo: What challenges does Harmony face, and how are you addressing them?

Jeffrey Dayno: One challenge is adapting to potential changes in regulatory standards and market dynamics. To navigate this, we’re expanding our clinical research efforts, engaging proactively with regulatory bodies, and building a robust internal infrastructure. As our pipeline grows, staying focused and rigorous in both development and commercialization is essential to our continued growth and impact.

Stoxpo: How does Harmony’s commitment to patient access factor into its long-term vision?

Jeffrey Dayno: Access is fundamental to Harmony’s mission. We’ve developed programs to assist patients with treatment costs and offer resources to healthcare providers to ease access barriers. Our ultimate aim is to build trust and establish Harmony as a reliable partner to patients, caregivers, and the broader medical community, making meaningful strides in neurological treatment options.

Previous Post

American Airlines in Talks with Citigroup for Exclusive Credit Card Deal

Next Post

Report Says Qualcomm Eyes Intel in Potential Takeover Bid

Related Posts

ProMIS Neurosciences Soars 160% After FDA Fast Track Designation for Alzheimer’s Drug

byLiliana Vida
July 21, 2025
0

PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients Shares of ProMIS Neurosciences...

Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025

byLuca Blaumann
July 7, 2025
0

Following a 38-to-1 stock split and explosive rally, the biotech firm's volatile trading persists despite a multi-year loss streak Regencell...

trading-chart-2

BitMine Raises $250 Million to Launch One of the Largest Public Ether Treasuries

byLuca Blaumann
June 30, 2025
0

Ethereum-focused strategy attracts top crypto investors as BitMine stock surges on bold treasury pivot BitMine Immersion Technologies (BMNR) has announced...

Next Post

Report Says Qualcomm Eyes Intel in Potential Takeover Bid

Latest News

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

Palo Alto Networks Eyes $20B Deal for CyberArk

Based on Your Interest

trading-chart
Ecommerece

AMD and Amazon: Two Titans Poised for Explosive Growth

July 28, 2025
Entertainment

FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy

July 25, 2025
airplane
Aerospace & Defense

FAA Keeps Boeing 737 MAX Production Cap in Place Amid Ongoing Oversight

July 24, 2025

Recommended

Large-Cap

Intel Beats on Revenue, Misses on Earnings; Cuts Workforce by 15%

July 24, 2025
Brokerages

Accelerant Soars in NYSE Debut, Valued at $6.4 Billion

July 24, 2025
Distributor

GoPro and Krispy Kreme Surge as Meme Stock Frenzy Reignites

July 23, 2025
Electrical Equipment

GE Vernova Soars to Record High on Raised Cash Flow Outlook

July 23, 2025
Auto Manufacturers

Earnings Season Surprises: Coca-Cola Delivers, GM Struggles Under Tariff Pressure

July 22, 2025
Stoxpo

Follow us on social media:

Highlights

  • Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom
  • Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk
  • Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million
  • Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth
  • Palo Alto Networks Eyes $20B Deal for CyberArk

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

trading-chart-2

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

August 4, 2025
tesla

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

August 4, 2025
evtol

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

August 4, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?